

11. Barkham N, Coates LC, Keen H, Hensor E, Fraser A, Redmond A, *et al.* Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. *Ann Rheum Dis* 2010;69:1926-8.
12. Corbett MS, M; Jhuti, G; Rice, S; Spackman, E; Sideris, E; Moe-Byrne, T; Fox, D; Marzo-Ortega, M; Kay, L; Woolacott, N; Palmer, S. TNF-alpha inhibitors for ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis (including a review of technology appraisal 143 and technology appraisal 233): Assessment Group Report. London, UK: National Institute for Health and Care Excellence,; 2014.
13. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J Clin Epidemiol* 2011;64:163-71.
14. Dohme MS. Clinical Study Report P006X01 (60-WEEK CSR): A Multicenter, Randomized, Double-blind, Placebo controlled Study of the Effect of Golimumab (GLM) Administered Subcutaneously (SC) in Subjects with Active Axial Spondyloarthritis (SpA) (Phase 3b, Protocol No. P07642, also known as MK8259-006-02, and as GOAHEAD); 2015.
15. National Institute for Health and Care Excellence. Resource impact report: TNF alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (including a review of TA143 and TA233) (TA383). London, UK: National Institute for Health and Care Excellence,; 2016.
16. British National Formulary. BNF Online June 2017. British Medical Association and the Royal Pharmaceutical Society. www.bnf.org/ (Accessed 20 July 2017).
17. Chapman SR, Fitzpatrick RW, Aladul MI. Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey. *BMJ Open* 2017;7:e016730.